Loading
When someone tests positive for a BRCA or Lynch mutation, relatives are told only if the patient passes the message on. Most do not. Letting clinics contact relatives directly, with consent, could double testing.
Cascade testing uptake is 20-40%. Trials of health-system-initiated direct contact (with proband consent) in the Netherlands and Australia show higher uptake. Propose direct contact as the default, with digital family letters, telegenetic counselling, and free mail-in testing for relatives regardless of their insurer.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, Germline (hereditary) testing.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified, Germline (hereditary) testing.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Germline vs somatic mutations, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified.
Shares Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified, Germline (hereditary) testing.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD).
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified, Germline (hereditary) testing.